Skip to main content
SpringerLink
Log in

Constraints on Antidepressant Prescribing and Principles of Cost-Effective Antidepressant Use

Part 1: Depression and its Treatment

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

Depression is a common, recurrent, disabling and potentially fatal disorder. Its effect on quality of life is more severe than that of some other chronic medical conditions. Its cost burden (direct and indirect) has been estimated at $US26 billion to $US43.7 billion in the US (in 1990), and 3.4 billion pounds sterling in the UK (in 1992).

With contemporary levels of diagnosis and treatment, and of treatment failure, the indirect economic losses to society from depression-associated morbidity and mortality may be up to 7 times the direct costs, with 69 to 98% of these costs related to morbidity. Impaired capacity while at work may equal absenteeism in terms of costs. Depression carries an increased risk of suicide and suicide attempts, both of which are costly. It is ironic, then, that the drugs used to treat depression account for 9% of poisoning deaths in England and Wales. The newer antidepressants are less toxic than the tricyclic antidepressants (TCAs).

The physician’s choice of antidepressant should be motivated primarily by clinical considerations, but cost implications are of increasing importance. In some healthcare systems, the expenditure associated with prescribing by doctors has been successfully modified, at least temporarily, by drug formularies, audit and feedback. This may be to the disadvantage of the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors; they have higher acquisition costs than the TCAs, since they are newer and lack cheaper generic forms, and definitive evidence of benefits may be inadequate or equivocal. However, market price is only one of many factors that should affect the prescriber, and the increasing trend towards cost containment policies is liable to lead to false economies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Montgomery SA, Bebbington P, Cowen P, et al. Guidelines for treating depressive illness with antidepressants. J Psychopharmacol 1993; 7(1): 19–23

    PubMed  CAS  Google Scholar 

  2. Regier DA, Hirschfeld RMA, Goodwin FK, et al. The NIMH depression awareness, recognition and treatment program: structure, aims and scientific basis. Am J Psychiatry 1988; 145: 1351–7

    PubMed  CAS  Google Scholar 

  3. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7: 191–5

    Article  PubMed  CAS  Google Scholar 

  4. Henry JA. Debits and credits in the management of depression. Br J Psychiatry 1993; 163 (20 Suppl.): 33–9

    Google Scholar 

  5. Hagnell O, editor. The incidence of mental illness over a quarter of a century. The Lundby longitudinal study of mental illness in a total population based on 42,000 observation years. Stockholm: Almkvist and Wiksell, 1990

    Google Scholar 

  6. Jablensky A. Prediction of the course and outcome of depression. Psychol Med 1987; 17: 1–9

    Article  PubMed  CAS  Google Scholar 

  7. Blacker CV, Clare AW. Depressive disorder in primary care. Br J Psychiatry; 150: 737–51

  8. Katon W, Roy-Byrne PP. Antidepressants in the medically ill: diagnosis and treatment in primary care. Clin Chem 1988; 34(5): 829–36

    PubMed  CAS  Google Scholar 

  9. Stoudemire A, Frank R, Hedemark N, et al. The economic burden of depression. Gen Hosp Psychiatry 1986; 8: 387–94

    Article  PubMed  CAS  Google Scholar 

  10. Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression: relation to the neurobiology of stress. N Engl J Med 1988; 319: 348–53

    Article  PubMed  CAS  Google Scholar 

  11. Wells KB, Stewart A, Hayes RD, et al. The functioning and well-being of depressed patients: results from the medical outcome study. JAMA 1989; 262(7): 914–19

    Article  PubMed  CAS  Google Scholar 

  12. Broadhead WE, Blazer DG, George LK, et al. Depression, disability days and days lost from work in a prospective epidemiologic study. JAMA 1990; 264: 2524–8

    Article  PubMed  CAS  Google Scholar 

  13. Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990; 12: 355–62

    Article  PubMed  CAS  Google Scholar 

  14. Wells KB, Golding JM, Burnam MA. Psychiatric disorder and limitations in physical functioning in a sample of the Los Angeles general population. Am J Psychiatry 1988; 145: 712–7

    PubMed  CAS  Google Scholar 

  15. Bridges K, Goldberg D. Somatic presentation of DSM-III psychiatric disorder in primary care. J Psychiatr Res 1985; 29: 563–9

    CAS  Google Scholar 

  16. Bridges K, Goldberg D. Somatic presentation of depressive illness in primary care. In: Freeling P, Downey LJ, Malkin JC, editors. The presentation of depression: current approaches. London: Royal College of General Practitioners, 1987

    Google Scholar 

  17. Goldberg D, Huxley P. Common mental disorders: a bio-social model. London: Routledge, 1992

    Google Scholar 

  18. von Korff M, Ormel J, Katon W, et al. Disability and depression among high utilizers of health care. Arch Gen Psychiatry 1992; 49: 91–100

    Article  Google Scholar 

  19. Weissman MM, Leaf PJ, Tischler GL, et al. Affective disorders in five United States communities. Psychol Med 1988; 18(1): 141–53

    Article  PubMed  CAS  Google Scholar 

  20. Weissman MM, Myers JK. Affective disorders in a US urban community: the use of research diagnostic criteria in an epidemiological survey. Arch Gen Psychiatry 1978; 35(11): 1304–11

    Article  PubMed  CAS  Google Scholar 

  21. Jonsson B, Bebbington P. Economic studies of the treatment of depressive illness. In: Jonsson B, Rosenbaum J, editors. Health economics of depression. New York: John Wiley, 1993: 35–48

    Google Scholar 

  22. Jonsson B, Bebbington P. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665–73

    Article  PubMed  CAS  Google Scholar 

  23. Coulehan JL, Schulberg HC, Block MR, et al. Medical comorbidity of major depressive disorder in a primary medical practice. Arch Intern Med 1990; 150(11): 2363–7

    Article  PubMed  CAS  Google Scholar 

  24. Office of Population Censuses and Surveys. Series VS No 15. London: OPCS, 1990

    Google Scholar 

  25. Turner R. Quality of life: experience with sertraline. Int Clin Psychopharmacol 1994; 9: 27–31

    Article  PubMed  Google Scholar 

  26. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54(11): 405–18

    PubMed  CAS  Google Scholar 

  27. Montgomery SA. Anxiety and depression. Petersfield: Wrightson Biomedical Publishing Ltd, 1990: 46, 59

    Google Scholar 

  28. Angst J, Vollrath M, Koch R. New aspects on epidemiology of depression. In: Angst J, Woggon B, editors. Lofepramine in the treatment of depressive disorders. Vieweg: Braunschweig, 1988: 1–14

    Google Scholar 

  29. Kocsis JH, Frances AJ, Voss C, et al. Imipramine treatment for chronic depression. Arch Gen Psychiatry 1988; 45: 253–7

    Article  PubMed  CAS  Google Scholar 

  30. Tsuang MT, Woolson JRF, Fleming JA. Premature deaths in schizophrenia and affective disorders. Arch Gen Psychiatry 1980; 37: 979–83

    Article  PubMed  CAS  Google Scholar 

  31. Guze SB, Robins E. Suicide and primary affective disorders. Am J Psychiatry 1970; 117: 437–8

    Article  CAS  Google Scholar 

  32. Winokur G, Tsuang M. The Iowa 500: suicide in mania, depression and schizophrenia. Am J Psychiatry 1975; 132: 650–3

    PubMed  CAS  Google Scholar 

  33. Barraclough BM, Bunch J, Nelson B, et al. A hundred cases of suicide: clinical aspects. Br J Psychiatry 1986; 125: 355–73

    Article  Google Scholar 

  34. Paykel ES. The treatment of depression: the relevance of research for clinical practice. Br J Psychiatry 1989; 155: 754–63

    Article  PubMed  CAS  Google Scholar 

  35. Levenson JL, Hamer RM, Rossiter LF. A randomized controlled study of psychiatric consultation guided by screening in general medical inpatients. Am J Psychiatry 1992; 149: 631–7

    PubMed  CAS  Google Scholar 

  36. Kellerman AL, Rivara FP, Somes G, et al. Suicide in the home in relation to gun ownership. N Engl J Med 1992; 327: 467–72

    Article  Google Scholar 

  37. Office of Population Censuses and Surveys, series DH4. Mortality statistics — accidents and violence (England and Wales). London: Her Majesty’s Stationery Office 1990, 1991, 1992

    Google Scholar 

  38. Office of Population Censuses and Surveys, series DH2. Mortality statistics — accidents and violence (England and Wales). London: Her Majesty’s Stationery Office, 1990, 1991, 1992, 1993

    Google Scholar 

  39. Goldstein RB, Black DW, Nasrallah A, et al. The prediction of suicide: sensitivity, specificity, and predictive value of a multivariate model applied to suicide among 1906 patients with affective disorders. Arch Gen Psychiatry 1991; 48: 418–22

    Article  PubMed  CAS  Google Scholar 

  40. Hawton K. Assessment of suicide risk. Br J Psychiatry 1987; 150: 145–53

    Article  PubMed  CAS  Google Scholar 

  41. Kreitman N. How useful is the prediction of suicide following parasuicide? In: Wilmotte J, Mendlewicz J, editors. New trends in suicide prevention. Basel: Karger, 1982

    Google Scholar 

  42. McNamee JE, Offord DR. Prevention of suicide. Can Med Assoc J 1990; 142: 1223–30

    CAS  Google Scholar 

  43. Motto JA. An integrated approach to estimating suicide risk. Suicide Life Threat Behav 1991; 21: 74–89

    PubMed  CAS  Google Scholar 

  44. Winokur G, Black DW. Suicide — what can be done? N Engl J Med 1992; 327: 490–1

    Article  PubMed  CAS  Google Scholar 

  45. Nordentoft M, Breum L, Munck LK, et al. High mortality by natural and unnatural causes: a 10 year follow up study of patients admitted to a poisoning treatment centre after suicide attempts. BMJ 1993; 306: 1637–41

    Article  PubMed  CAS  Google Scholar 

  46. Murphy GE. Suicide and substance abuse. Arch Gen Psychiatry 1988; 45: 593–4

    Article  PubMed  CAS  Google Scholar 

  47. Prescott LF, Highley MS. Drugs prescribed for self poisoners. BMJ 1985; 290: 1633–6

    Article  PubMed  CAS  Google Scholar 

  48. Weissman MM, Klerman GL, Prusoff BA, et al. Depressed outpatients: results one year after treatment with drugs and/or interpersonal psychotherapy. Arch Gen Psychiatry 1981; 38: 51–5

    Article  PubMed  CAS  Google Scholar 

  49. Weissman MM. The psychological treatment of depression: update of clinical trials. In: Williams JBW, Spitzer RL, eds. Psychotherapy research: where are we and where should we go? New York: Guilford Press, 1984: 89–105

    Google Scholar 

  50. Gerner R, Estabrook W, Steuer J, et al. Treatment of geriatric depression with trazodone, imipramine and placebo: a double-blind study. J Clin Psychiatry 1980; 41: 216–220

    PubMed  CAS  Google Scholar 

  51. Thompson C, Thompson CM. The prescribing of antidepressants in general practice II. A placebo-controlled trial of low-dose dothiepin. Hum Psychopharmacol 1989; 4: 191–204

    Article  Google Scholar 

  52. West R. Depression. London: Office of Health Economics, 1992

    Google Scholar 

  53. Abraham IL, Bryant Neese J, Westerman PS. Depression: nursing implications of a clinical and social problem. Nurs Clin North Am 1991; 26(3): 527–36

    PubMed  CAS  Google Scholar 

  54. Feighner JP. A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients. In: Ashcroft GW, editor. Depression — a once in a lifetime event? Oxford: Clinical Neuroscience Publishers, 1991

    Google Scholar 

  55. Mendlewicz J. The social burden of depressive disorders. Neuropsychobiology 1989; 22: 178–80

    Article  PubMed  CAS  Google Scholar 

  56. Rice DP. Conceptual and estimation issues related to cost of illness studies [abstract]. The Second Workshop of Cost and Assessment in Psychiatry: the costs of affective disorders. 1992 Oct 26–28; Venice

  57. McGuire TG. Outcomes, costs and design of health insurance for depression. In: Jonsson B, Rosenbaum J, editors. Health economics of depression: perspectives in psychiatry, Vol 4. Chichester: Wiley, 1993: 77–96

    Google Scholar 

  58. Croft-Jeffreys C, Wilkinson G. Estimated costs of neurotic disorder in UK general practice 1985. Psychol Med 1989; 19: 549–58

    Article  PubMed  CAS  Google Scholar 

  59. Hertzman P. The economic costs of mental illness in Sweden 1975. Acta Psychol (Scand) 1983; 68: 359–67

    Article  CAS  Google Scholar 

  60. McCombs JS, Nichol MB. The cost of treatment failure. In: Jonsson B, Rosenbaum J, editors. Health economics of depression: perspectives in psychiatry, Vol 4. Chichester: Wiley, 1993: 49–64

    Google Scholar 

  61. Walinder J, Carlsson P, Rutz W. The economic impact of an educational programme on diagnosis and treatment of depression in Sweden. In: Jonsson B, Rosenbaum J, editors. Health economics of depression: perspectives in depression, Vol 4. Chichester: Wiley, 1993: 97–110

    Google Scholar 

  62. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992; 326: 862–6

    Article  PubMed  CAS  Google Scholar 

  63. Eisenberg JM, Glick H, Koffer H. Pharmacoeconomics: economic evaluation of Pharmaceuticals. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989: 325–50

    Google Scholar 

  64. Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of major health impairments. Lexington: Lexington Books, 1980

    Google Scholar 

  65. Weisbrod BA. Benefit-cost analysis of a controlled experiment treating the mentally ill. J Hum Resour 1981; 16: 523–48

    Article  PubMed  CAS  Google Scholar 

  66. Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976: 39: 21–36

    PubMed  CAS  Google Scholar 

  67. Black DAK, Pole JD. Priorities in biomedical research: indices of burden. Br J Prevent Med 1975; 29(4): 222–7

    CAS  Google Scholar 

  68. Weisbrod BA. Economics of mental illness: costs, benefits and incentives. In: Jonsson B, Rosenbaum J, editors. Health economics of depression: perspectives in psychiatry, Vol 4. Chichester: Wiley, 1993: 15–34

    Google Scholar 

  69. Rice DP, Kelman S, Miller LS. Estimates of economic costs of alcohol and drug abuse and mental illness, 1985 and 1988. Public Health Rep 1991; 106(3): 280–92

    PubMed  CAS  Google Scholar 

  70. Drummond MF, Stodden GL, Torrence G. Methods for the economic evaluation of healthcare programmes. Oxford: Oxford Medical, 1987

    Google Scholar 

  71. von Korff M, Ormel J, Katon W, et al. Disability and depression among high utilizers of health care. Arch Gen Psychiatry 1992; 49: 91–100

    Article  Google Scholar 

  72. Montgomery SA. Suicide and antidepressants. Drugs 1992; 43 Suppl.: 24–31

    Article  PubMed  Google Scholar 

  73. Kiloh LG, Andrews G, Neilson M. The long-term outcome of depressive illness. Br J Psychiatry 1988; 153: 752–57

    Article  PubMed  CAS  Google Scholar 

  74. Bulik CM, Carpenter LL, Kupfer DJ, et al. Features associated with suicide attempts in recurrent major depression. J Affect Disord 1990; 18(1): 29–37

    Article  PubMed  CAS  Google Scholar 

  75. Angst J, Stassen HH, Gross G, et al. Suicide in affective and schizoaffective disorders. In: Marneros A, Tsuang MT, editors. Affective and schizoaffective disorders. Berlin: Springer Verlag, 1990: 186–95

    Google Scholar 

  76. Weinstein MC, Saturno PJ. Economic impact of youth suicide and suicide attempts. In: US DHSS Publication: 1982–1989. Rockville: Department of Health and Human Services, 1989: ADM 89-1264

    Google Scholar 

  77. Wells KB. Depression as a tracer condition for the national study of medical care outcomes: background review. Rand Corporation 1985: R-3293-RWJ/HJK

    Google Scholar 

  78. Eaton WW, Holzer CE III, von Korff M, et al. The design of the Epidemiological Catchment Area surveys: the control and measurement of error. Arch Gen Psychiatry 1984; 41: 942

    Article  PubMed  CAS  Google Scholar 

  79. Pettito JM, Folds JD, Ozer H, et al. Abnormal diurnal variation in circulating natural killer cell phenotypes and cytotoxic activity in major depression. Am J Psychiatry 1992; 149: 694–6

    Google Scholar 

  80. Robinson RG, Starr LB, Price TR. A two year longitudinal study of mood disorder following stroke: prevalence and duration at six months follow-up. Br J Psychiatry 1984; 144: 256–62

    Article  PubMed  CAS  Google Scholar 

  81. Babigian HM, Guttmacher LB. Epidemiologic considerations in electroconvulsive therapy. Arch Gen Psychiatry 1984; 41: 246–53

    Article  PubMed  CAS  Google Scholar 

  82. Rovner BW, German PS, Brant LJ, et al. Depression and mortality in nursing homes. JAMA 1991; 265(8): 993–6

    Article  PubMed  CAS  Google Scholar 

  83. Goodwin GM. The effects of treatment on mortality in affective illness. J Psychopharmacol 1992; 6: 312–7

    PubMed  CAS  Google Scholar 

  84. Thompson D, Pudney M. Mental illness: the fundamental facts. London: Mental Health Foundation, 1989

    Google Scholar 

  85. Jenkins R. Minor psychiatric morbidity in employed young men and women and its contribution to sickness absence. Br J Ind Med 1985; 42: 147–54

    PubMed  CAS  Google Scholar 

  86. Angst J. Epidemiology of depression. Psychopharmacology (Berl) 1992; 106 Suppl.: 71S–4S

    Article  Google Scholar 

  87. Bech P, Dunbar GC, Stoker MJ. The challenge of measuring quality of life in psychiatric patients. In: Jonsson B, Rosenbaum J, editors. Health economics of depression: perspectives in psychiatry, Vol 4. Chichester: Wiley, 1993: 111–28

    Google Scholar 

  88. Slevin ML, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988; 57: 109–12

    Article  PubMed  CAS  Google Scholar 

  89. Olsen JA. Persons vs years: two ways of eliciting implicit weights. Health Econ 1994; 3: 39–46

    Article  PubMed  CAS  Google Scholar 

  90. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chron Dis 1978; 31: 697–704

    Article  PubMed  CAS  Google Scholar 

  91. Kaplan RM, Anderson JP. A general health policy model: update and applications. J Health Serv Res 1988; 23: 203–35

    CAS  Google Scholar 

  92. Simon G, Wagner E, Von Korff M. Cost-effectiveness comparisons using ‘real world’ randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995; 48: 363–73

    Article  PubMed  CAS  Google Scholar 

  93. O’Brien BJ, Novosel S, Torrance G, et al. Assessing the economic value of a new antidepressant: a willingness-to-pay approach. Pharmacoeconomics 1995; 8: 34–45

    Article  PubMed  Google Scholar 

  94. Toufexis A. The personality pill. Time 1993 Oct 11; 76–7

    Google Scholar 

  95. Lee AS, Murray RM. The long-term outcome of Maudsley depressives. Br J Psychiatry 1988; 153: 741–51

    Article  PubMed  CAS  Google Scholar 

  96. WHO Mental Health Collaborating Centres, 1989

  97. Boyer WF, Feighner JP. In: Jonsson B, Rosenbaum J, editors. Health economics of depression: perspectives in psychiatry, Vol. 4. Chichester: Wiley, 1993: 65–76

  98. Mindham RH, Howland C, Shepherd M. Continuation therapy with tricyclic antidepressants in depressive illness. Lancet 1987; II: 854–55

    Google Scholar 

  99. Prien R, Kupfer D. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986; 143: 18–23

    PubMed  CAS  Google Scholar 

  100. Weissman MM, Klerman GL. Epidemiology of mental disorders: emerging trends in the United States. Arch Gen Psychiatry 1978; 35(6): 705–12

    Article  PubMed  CAS  Google Scholar 

  101. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769–73

    Article  PubMed  CAS  Google Scholar 

  102. Greden JF. Antidepressant maintenance medications: when to discontinue and how to stop. J Clin Psychiatry 1993; 54: 39–45

    PubMed  Google Scholar 

  103. Old Age Depression Interest Group. How long should the elderly take antidepressants? Br J Psychiatry 1993; 162: 175–82

    Article  Google Scholar 

  104. Prien RF, Klett CJ, Caffey EM. Lithium carbonate and imipramine in the prevention of affective episodes. Arch Gen Psychiatry 1973; 29: 420–25

    Article  PubMed  CAS  Google Scholar 

  105. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992: 160: 217–22

    Article  PubMed  CAS  Google Scholar 

  106. Hirschfeld RMA, Goodwin FK. Mood disorders. In: Talbott JA, Yudowsky SC, editors. Textbook of psychiatry. Washington, DC: American Psychiatric Press, 1988

    Google Scholar 

  107. Baldessarini RJ. Current status of antidepressants: clinical pharmacology and therapy. J Clin Psychiatry 1989; 50: 117–26

    PubMed  CAS  Google Scholar 

  108. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990; 51(6): 60–72

    PubMed  Google Scholar 

  109. Katon W, von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30: 67–76

    Article  PubMed  CAS  Google Scholar 

  110. Berlanga C, Ortega-Soto HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J Affect Disord 1995; 34: 187–92

    Article  PubMed  CAS  Google Scholar 

  111. Tiller J, Mitchell P, Burrows GD. Monoamine oxidase inhibitors (MAOI) or reversible inhibitors of monoamine oxidase (RIMA) tricyclic (TCA) combination therapy. Aust N Z J Psychiatry 1992; 26: 327–9

    Article  PubMed  CAS  Google Scholar 

  112. Grounds D. On combining TCAs and MAOIs. Aust N Z J Psychiatry 1993; 26: 327–9

    Google Scholar 

  113. Johnson FN. The evolution of lithium therapy. J Psychopharmacol 1992; 6: 325–9

    PubMed  CAS  Google Scholar 

  114. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137: 782–90

    PubMed  CAS  Google Scholar 

  115. Robinson DS, Nies A, Ravaris L, et al. Clinical pharmacology of phenelzine. Arch Gen Psychiatry 1978, 35: 629–35

    Article  PubMed  CAS  Google Scholar 

  116. Roper Reports. Report to Medicaid: what people do for minor health problems. New York: Roper Organization, 1986: 86–8.

  117. Johnson DAW. Non-compliance with antidepressant therapy: an underestimated problem. Intern Med 1986; 11 Suppl.: 14–7

    Google Scholar 

  118. Waters WH, Gould NV, Lunn JE. Undispensed prescriptions in a mining general practice. BMJ 1976; 1: 1062–3

    Article  PubMed  CAS  Google Scholar 

  119. Begg D. Do patients cash prescriptions? An audit in one practice. J R Coll Gen Pract 1984; 34: 272–4

    PubMed  CAS  Google Scholar 

  120. Rashid A. Do patients cash prescriptions? BMJ 1982; 284: 24–6

    Article  PubMed  CAS  Google Scholar 

  121. Beardon PH, McGilchrist MM, McKendrick AD, et al. Primary non-compliance with prescribed medication in primary care. BMJ 1993; 307: 846–8

    Article  PubMed  CAS  Google Scholar 

  122. Murray J, Shepherd S. Alternative or additional medicine? A new dilemma for the doctor. J R Coll Gen Pract 1988; 38: 511–4

    PubMed  CAS  Google Scholar 

  123. Corney RH. Marital problems and treatment outcome in depressed women: a clinical trial of social work intervention. Br J Psychiatry 1987; 151: 652–9

    Article  PubMed  CAS  Google Scholar 

  124. Freeling P, Harris CM. The doctor/patient relationship. London: Churchill Livingstone, 1984

    Google Scholar 

  125. Hawton K. Controlled studies of psychosocial intervention following attempted suicide. In: Kreitman N, Platt S, editors. Current research on suicide and parasuicide. Edinburgh: Edinburgh University Press, 1989

    Google Scholar 

  126. Rosenberg NK. Psychotherapy of the suicidal patient. Acta Psychiatr Scand 1993; 371 Suppl.: 54–6

    Article  CAS  Google Scholar 

  127. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health treatment of depression collaborative research program: general effectiveness of treatments. Arch Gen Psychiatry 1989; 46: 971–82

    Article  PubMed  CAS  Google Scholar 

  128. Paykel ES, Dirlascio A, Haskell D, et al. Effects of maintenance amitriptyline and psychotherapy on symptoms of depression. Psychol Med 1975; 5: 67–77

    Article  PubMed  CAS  Google Scholar 

  129. Sturm R, Wells KB. How can care for depression become more cost-effective? JAMA 1995; 273: 51–8

    Article  PubMed  CAS  Google Scholar 

  130. Blackburne IM, Bishop S, Glen IM, et al. The efficacy of cognitive treatment in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. Br J Psychiatry 1981; 139: 181–9

    Article  Google Scholar 

  131. Teasdale JD, Fennell MJV, Hibbert GA, et al. Cognitive therapy for major depressive disorders in primary care. Br J Psychiatry 1984; 144: 400–6

    Article  PubMed  CAS  Google Scholar 

  132. Rush AJ, Beck AT, Kovacs M, et al. Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. Cognit Ther Res 1977; 1: 17–37

    Article  Google Scholar 

  133. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes. for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 1093–9

    Article  PubMed  CAS  Google Scholar 

  134. Agency of Health Care Policy and Research — Depression Guideline Panel. Depression in Primary Care, vol. 2. Treatment of major depression. Clinical practice guideline 5. Rockville (MD): US Dept of Health and Human Services, 1993; ACHPR Publication 93-0551

    Google Scholar 

  135. Avery D, Winokur G. The efficacy of electroconvulsive therapy and antidepressants in depression. Biol Psychiatry 1977; 12: 507–23

    PubMed  CAS  Google Scholar 

  136. Sack DA, Nurnberger J, Rosenthal NE, et al. The potentiation of antidepressant medications by phase advance of the sleep-wake cycle. Am J Psychiatry 1985; 142: 606–8

    PubMed  CAS  Google Scholar 

  137. Schligen B, Tolle R. Partial sleep deprivation as therapy for depression. Arch Gen Psychiatry 1980; 37: 267–71

    Article  Google Scholar 

  138. Glaser WA. The politics of paying physicians. Health Aff 1989; 8: 129–46

    Article  CAS  Google Scholar 

  139. Jonsson B. The pharmaceutical market. In: Bourdet, editor. Internationalisation, market power and consumer welfare. London: Routledge, 1992

    Google Scholar 

  140. Association of the British Pharmaceutical Industry. Pharma Facts and Figures. London: ABPI, 1992

    Google Scholar 

  141. European Federation of Pharmaceutical Industries’ Associations. The pharmaceutical industry in Europe 1990–1991. EFPIA, 1992

  142. Coney S. NZ’s Pharmac tackles antidepressant bill. Lancet 1994; 344: 463–4

    Article  Google Scholar 

  143. McLeod AJ. Rational prescribing [letter]. BMJ 1994; 308: 1573

    Article  Google Scholar 

  144. Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37: 33–40

    Article  PubMed  CAS  Google Scholar 

  145. Rucker TD, Schiff G. Drug formularies: myths-in-formation. Med Care 1990; 28(10): 928–42

    Article  PubMed  CAS  Google Scholar 

  146. Shepherd MD, Salzman RD. The formulary decision-making process in a health maintenance organisation setting. Pharmacoeconomics 1994; 5(1): 29–38

    Article  PubMed  CAS  Google Scholar 

  147. Bochner F, Martin DE, Burgess NG, et al. Drug rationing in a teaching hospital: a method to assign priorities. BMJ 1994; 308: 901–5

    Article  PubMed  CAS  Google Scholar 

  148. Donaldson C. Formulate, don’t formularise. BMJ 1994; 308: 905–6

    Article  PubMed  CAS  Google Scholar 

  149. Petrie JC. First consider the overall process of care [letter]. BMJ 1994; 308: 906

    Article  PubMed  CAS  Google Scholar 

  150. Chadwick R. Fairness is at issue [letter]. BMJ 1994; 308: 907–8

    Article  PubMed  CAS  Google Scholar 

  151. Drummond MF. The economics of drug formularies. Pharm J 1989; 15: 451–2

    Google Scholar 

  152. Hanson ES, Shepherd MD, Pleil A, et al. How P&T committee members in HMSOs make formulary decisions. PT 1992; 17: 247–54

    Google Scholar 

  153. Taylor S, McLean P. Outcome profiles in the treatment of unipolar depression. Behav Res Ther 1992; 31(3): 325–30

    Article  Google Scholar 

  154. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310: 221–4

    Article  PubMed  CAS  Google Scholar 

  155. Montgomery SA, Henry JA, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47–54

    Article  PubMed  CAS  Google Scholar 

  156. Sloan FA, Gordon GS, Cocks DL. Hospital drug formularies and use of hospital services. Med Care 1993; 31(10): 851–67

    Article  PubMed  CAS  Google Scholar 

  157. Pearce MJ, Begg EJ. A review of limited lists and formularies. Pharmacoeconomics 1992; 1(3): 191–202

    Article  PubMed  CAS  Google Scholar 

  158. Hazlet TK, Hu TW. Association between formulary strategies and hospital drug expenditure. Am J Hosp Pharm 1992; 49(9): 2207–10

    PubMed  CAS  Google Scholar 

  159. Scrip 26 Mar 1996

  160. Raisch DW. Relationship among prescription payment methods and interactions between community pharmacists and prescribers. Ann Pharmacother 1992; 26(7–8): 902–6

    PubMed  CAS  Google Scholar 

  161. Goldberg D, Gater R. Estimates of need. Psychiatr Bull 1991; 15: 593–5

    Article  Google Scholar 

  162. Thompson C, Thompson CM. The prescription of antidepressants in general practice: a critical review. Hum Psychopharmacol 1989; 4: 91–102

    Article  Google Scholar 

  163. Bradlow J, Coulter A. Effect of fundholding and indicative prescribing schemes on general practitioners’ prescribing costs. BMJ 1993; 307: 1186–9

    Article  PubMed  CAS  Google Scholar 

  164. Bligh J, Walley T. The UK Indicative Prescribing Scheme. Pharmacoeconomics 1992; 2(2): 137–52

    Article  PubMed  CAS  Google Scholar 

  165. Bradley C. Decision making and prescribing patterns: a literature review. Fam Prac 1991; 8(3): 276–87

    Article  CAS  Google Scholar 

  166. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach: a randomized control trial of academically based ‘detailing’. N Engl J Med 1983; 308: 1457–63

    Article  PubMed  CAS  Google Scholar 

  167. Gehlbach SH, Wilkinson WE, Hammond WE, et al. Improving drug prescribing in a primary care practice. Med Care 1984; 22: 193–201

    Article  PubMed  CAS  Google Scholar 

  168. Harris CM, Jarman B, Woodman E, et al. Prescribing: a case for treatment. London: Royal College of General Practitioners, 1984: occasional paper no. 24

    Google Scholar 

  169. Hux JE, Naylor CD. Drug prices and third party payment: do they influence medical selection? Pharmacoeconomics 1994; 5(4): 343–50

    Article  PubMed  CAS  Google Scholar 

  170. Jabbari B, Bryan GE, Marsh EE, et al. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 1985; 42(5): 480–1

    Article  PubMed  CAS  Google Scholar 

  171. Hale AS. New antidepressants: use in high-risk patients. J Clin Psychiatry 1993; 54 (8 Suppl.): 61–70

    PubMed  Google Scholar 

  172. Overall JE. Efficacy of nomifensine in different depressive syndromes. J Clin Psychiatry 1984; 45(4): 85–8

    PubMed  CAS  Google Scholar 

  173. Boyer WF. Potential indications for the SSRIs. Int Clin Psychopharmacol 1992; 53: 61–6

    Google Scholar 

  174. Wakelin JS, Coleman BS. The influence of the 5-HT specific antidepressant, fluvoxamine maleate, on suicidal behaviour [abstract]. Int J Neurosci 1986; 31: 216

    Google Scholar 

  175. Mullin JM, Pandita-Gunawardena VR, Whitehead AM. A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. Br J Clin Prac 1988; 42(2): 51–5

    CAS  Google Scholar 

  176. Sacchetti E, Vita A, Guarneri L et, al. The effectiveness of fluoxetine, clomipramine, nortriptyline and desipramine in major depressives with suicidal behaviour: preliminary findings. In: Casano GB, Akiskal HS, editors. Serotonin-related psychiatric syndromes: clinical and therapeutic links. London: Royal Society of Medicine, 1991 (International Congress and Symposium Series; 165)

    Google Scholar 

  177. Feldman HS, Denber HC. Long-term study of fluvoxamine: a new rapid-acting antidepressant. Int Pharmacopsychiatry 1982; 17: 114–22

    Google Scholar 

  178. Henry JA, Martin AJ. The risk-benefit assessment of antidepressant drugs. Med Toxicol 1987; 2: 445–62

    Article  CAS  Google Scholar 

  179. Muijen M, Roy D, Silverstone T, et al. A comparative clinical trial of fluoxetine, mianserin and placebo with depressed out-patients. Acta Psychiatr Scand 1988; 78: 384–90

    Article  PubMed  CAS  Google Scholar 

  180. Wakelin J. The role of serotonin in depression and suicide. Adv Biol Psychiatry 1988; 17: 70–83

    Google Scholar 

  181. de Wilde JEM, Doogan DP. Fluvoxamine and clomipramine in endogenous depression. J Affec Disord 1982; 4: 249–59

    Article  Google Scholar 

  182. Martin AJ, Tebbs VM, Ashford JJ. Affective disorders in general practice: treatment of 6000 patients with fluvoxamine. Pharmatherapeutica 1987; 5: 40–8

    PubMed  CAS  Google Scholar 

  183. Montgomery SA, Pinder RM. Do some antidepressants promote suicide? Psychopharmacology 1987; 92: 265–6

    Article  PubMed  CAS  Google Scholar 

  184. Montgomery SA, McAulay R, Rani SJ. A double blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatr Scand 1981; 63: 314–27

    Article  Google Scholar 

  185. Damluji NF, Ferguson JM. Paradoxical worsening of depressive symptomatology caused by antidepressants. J Clin Psychopharmacol 1988; 8(5): 347–9

    Article  PubMed  CAS  Google Scholar 

  186. Beasley CM, Dornseif BE, Bosomworth MES, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment of depression. BMJ 1991; 303: 665–92

    Article  Google Scholar 

  187. Fava M, Rosenbaum JF. Suicidality and fluoxetine — is there a relationship? J Clin Psychiatry 1991; 52: 108–11

    PubMed  CAS  Google Scholar 

  188. Rouillon R, Philips R, Serrurier D, et al. Rechutes du depression unipolaire et efficacite de la maprotiline. L’Encephale 1993; XV: 527–34

    Google Scholar 

  189. Feuerstein TJ, Jakisch R. Why do some antidepressants promote suicide [letter]? Psychopharmacol 1986; 90: 422

    CAS  Google Scholar 

  190. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217–22

    Article  PubMed  CAS  Google Scholar 

  191. Wernicke JF, Bosomworth JC, Ashbrook E. Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depression. Int Clin Psychopharmacol 1989; 4 Suppl. 1: 63–7

    PubMed  Google Scholar 

  192. Weissman MM. The epidemiology of suicide attempts, 1960–1971. Arch Gen Psychiatry 1974; 30: 737–46

    Article  PubMed  CAS  Google Scholar 

  193. Johnson DAW. Depression: treatment compliance in general practice. Acta Psychiatr Scand 1981; 63: 447–53

    Article  Google Scholar 

  194. Johnson DAW. Antidepressant treatment observed: some problems of compliance by doctors and patients. In: Sims, Ottofson, editors. Antidepressants: progress in problem areas. London: Franklin Scientific Projects, 1984

    Google Scholar 

  195. Canino GJ, Bird HR, Shrout PE, et al. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry 1987; 44(8): 727–35

    Article  PubMed  CAS  Google Scholar 

  196. Blacker CVR, Clare AW. The prevalence and treatment of depression in general practice. Psychopharmacol 1988; 95: 14–17

    Google Scholar 

  197. Keller MB, Klerman GL, Lavori PW, et al. Treatment received by depressed patients. JAMA 1982; 248(15): 1848–55

    Article  PubMed  CAS  Google Scholar 

  198. Tyrer P. Drug treatment of psychiatric patients in general practice. BMJ 1978: 2: 1008–10

    Article  PubMed  CAS  Google Scholar 

  199. Kass F, Charles E, Walsh T, et al. Quality review of outpatient psychopharmacological practice with APA Task Force criteria. Am J Psychiatry 1983; 140(2): 221–4

    PubMed  CAS  Google Scholar 

  200. Fish D: What is an effective dose [letter]? BMJ 1997; 314: 826

    Article  PubMed  CAS  Google Scholar 

  201. Gill D. Systematic review of all pertinent trials is required to establish guidelines [letter]. BMJ 1997; 314: 826–7

    Article  PubMed  CAS  Google Scholar 

  202. Tan RS. Low dose tricyclic antidepressants are effective in treating major depression [letter]. BMJ 1997; 314: 827

    PubMed  CAS  Google Scholar 

  203. Gorham PN. Who bears the cost of antidepressants in Australia? Med J Aust 1995; 162: 162–3

    PubMed  CAS  Google Scholar 

  204. Maxwell M, Heaney D, Howie JGR, et al. General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method. BMJ 1993; 307: 1190–4

    Article  PubMed  CAS  Google Scholar 

  205. Griffin JP, Griffin TD. The economic implications of therapeutic conservatism. J R Coll Physicians Lond 1993; 27(2): 121–6

    PubMed  CAS  Google Scholar 

  206. Goldstein AO, Ives TJ. Depression treatment. J Fam Pract 1994; 38: 49–57

    Google Scholar 

  207. Kind P, Sorensen J. Modelling the cost-effectiveness of the prophylactic use of SSRIs in the treatment of depression. Int Clin Psychopharmacol 1995; 10: 41–8

    Article  PubMed  Google Scholar 

  208. Le Pen C, Levy E, Ravily V, et al. The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine vs tricyclics. J Affect Disord 1994; 31: 1–18

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St Mary’s Hospital, London, England

    John A. Henry & Carol A. Rivas

Authors
  1. John A. Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol A. Rivas
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Henry, J.A., Rivas, C.A. Constraints on Antidepressant Prescribing and Principles of Cost-Effective Antidepressant Use. PharmacoEconomics 11, 419–443 (1997). https://doi.org/10.2165/00019053-199711050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199711050-00005

Keywords

Search

Navigation